Idalopirdine is primarily investigated for its potential application in the treatment of cognitive disorders, particularly Alzheimer's disease. It functions as a selective antagonist of the 5-HT6 receptor, which is believed to play a role in cognitive processes. By modulating this receptor, it aims to improve memory and cognitive function in patients with neurodegenerative conditions. Clinical studies have explored its efficacy in enhancing cognitive performance, though results have been mixed, leading to further research to better understand its therapeutic potential. It represents a targeted approach to addressing the cognitive symptoms associated with Alzheimer's disease.